

Matthew C Pickering

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2946948/publications.pdf>

Version: 2024-02-01

120
papers

8,976
citations

38660

50
h-index

42291

92
g-index

125
all docs

125
docs citations

125
times ranked

6876
citing authors

#	ARTICLE	IF	CITATIONS
1	C3 glomerulopathy: consensus report. <i>Kidney International</i> , 2013, 84, 1079-1089.	2.6	505
2	Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. <i>Nature Genetics</i> , 2002, 31, 424-428.	9.4	461
3	Intracellular Complement Activation Sustains T Cell Homeostasis and Mediates Effector Differentiation. <i>Immunity</i> , 2013, 39, 1143-1157.	6.6	444
4	C3 glomerulopathy: a new classification. <i>Nature Reviews Nephrology</i> , 2010, 6, 494-499.	4.1	314
5	Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. <i>Lancet, The</i> , 2010, 376, 794-801.	6.3	298
6	Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. <i>Journal of Experimental Medicine</i> , 2007, 204, 1249-1256.	4.2	267
7	Complement in human diseases: Lessons from complement deficiencies. <i>Molecular Immunology</i> , 2009, 46, 2774-2783.	1.0	250
8	Dimerization of complement factor H-related proteins modulates complement activation in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 4685-4690.	3.3	243
9	Atypical aHUS: State of the art. <i>Molecular Immunology</i> , 2015, 67, 31-42.	1.0	236
10	New Approaches to the Treatment of Dense Deposit Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 2447-2456.	3.0	231
11	C3 glomerulopathy “ understanding a rare complement-driven renal disease. <i>Nature Reviews Nephrology</i> , 2019, 15, 129-143.	4.1	223
12	Complement factor H deficiency in aged mice causes retinal abnormalities and visual dysfunction. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 16651-16656.	3.3	201
13	C3 Glomerulopathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 46-53.	2.2	192
14	C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation. <i>Journal of Clinical Investigation</i> , 2013, 123, 2434-2446.	3.9	176
15	Translational Mini-Review Series on Complement Factor H: Renal diseases associated with complement factor H: novel insights from humans and animals. <i>Clinical and Experimental Immunology</i> , 2008, 151, 210-230.	1.1	165
16	The complement system as a potential therapeutic target in rheumatic disease. <i>Nature Reviews Rheumatology</i> , 2017, 13, 538-547.	3.5	147
17	Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 9649-9654.	3.3	144
18	Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 95, 281-295.	2.6	135

#	ARTICLE	IF	CITATIONS
19	Complement Factor H Inhibits CD47-Mediated Resolution of Inflammation. <i>Immunity</i> , 2017, 46, 261-272.	6.6	132
20	High Prevalence of Asymptomatic COVID-19 Infection in Hemodialysis Patients Detected Using Serologic Screening. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 1969-1975.	3.0	128
21	A Hybrid CFHR3-1 Gene Causes Familial C3 Glomerulopathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 1155-1160.	3.0	120
22	Factor I is required for the development of membranoproliferative glomerulonephritis in factor H-deficient mice. <i>Journal of Clinical Investigation</i> , 2008, 118, 608-18.	3.9	118
23	P2X7 Deficiency Attenuates Renal Injury in Experimental Glomerulonephritis. <i>Journal of the American Society of Nephrology: JASN</i> , 2009, 20, 1275-1281.	3.0	105
24	The Development of Atypical Hemolytic Uremic Syndrome Depends on Complement C5. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 137-145.	3.0	105
25	Circulating complement factor H-related proteins 1 and 5 correlate with disease activity in IgA nephropathy. <i>Kidney International</i> , 2017, 92, 942-952.	2.6	99
26	Acute Presentation and Persistent Glomerulonephritis Following Streptococcal Infection in a Patient With Heterozygous Complement Factor H-Related Protein 5 Deficiency. <i>American Journal of Kidney Diseases</i> , 2012, 60, 121-125.	2.1	95
27	Treatment with human complement factor H rapidly reverses renal complement deposition in factor H-deficient mice. <i>Kidney International</i> , 2010, 78, 279-286.	2.6	94
28	Histopathology of MPGN and C3 glomerulopathies. <i>Nature Reviews Nephrology</i> , 2015, 11, 14-22.	4.1	91
29	Complement Component C3 Plays a Critical Role in Protecting the Aging Retina in a Murine Model of Age-Related Macular Degeneration. <i>American Journal of Pathology</i> , 2013, 183, 480-492.	1.9	81
30	Dense deposit disease. <i>Molecular Immunology</i> , 2011, 48, 1604-1610.	1.0	80
31	The role of complement in C3 glomerulopathy. <i>Molecular Immunology</i> , 2015, 67, 21-30.	1.0	78
32	Detection of complement activation using monoclonal antibodies against C3d. <i>Journal of Clinical Investigation</i> , 2013, 123, 2218-2230.	3.9	78
33	The role of complement in IgA nephropathy. <i>Molecular Immunology</i> , 2019, 114, 123-132.	1.0	76
34	Factor H-Related Protein 5 Interacts with Pentraxin 3 and the Extracellular Matrix and Modulates Complement Activation. <i>Journal of Immunology</i> , 2015, 194, 4963-4973.	0.4	75
35	Complement and glomerular disease: new insights. <i>Current Opinion in Nephrology and Hypertension</i> , 2011, 20, 271-277.	1.0	71
36	Recent insights into C3 glomerulopathy. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 1685-1693.	0.4	70

#	ARTICLE	IF	CITATIONS
37	The follicular dendritic cell restricted epitope, FDC-M2, is complement C4; localization of immune complexes in mouse tissues. <i>European Journal of Immunology</i> , 2002, 32, 1883.	1.6	68
38	A novel CFHR5 fusion protein causes C3 glomerulopathy in a family without Cypriot ancestry. <i>Kidney International</i> , 2014, 85, 933-937.	2.6	61
39	Phagocytosis Is the Main CR3-Mediated Function Affected by the Lupus-Associated Variant of CD11b in Human Myeloid Cells. <i>PLoS ONE</i> , 2013, 8, e57082.	1.1	58
40	An extended mini-complement factor H molecule ameliorates experimental C3 glomerulopathy. <i>Kidney International</i> , 2015, 88, 1314-1322.	2.6	58
41	Longitudinal proteomic profiling of dialysis patients with COVID-19 reveals markers of severity and predictors of death. <i>ELife</i> , 2021, 10, .	2.8	58
42	Complement Factor H Limits Immune Complex Deposition and Prevents Inflammation and Scarring in Glomeruli of Mice with Chronic Serum Sickness. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 52-57.	3.0	57
43	Dense Deposit Disease and C3 Glomerulopathy. <i>Seminars in Nephrology</i> , 2013, 33, 493-507.	0.6	57
44	Progressive IgA Nephropathy Is Associated With Low Circulating Mannan-Binding Lectin-Associated Serine Protease-3 (MASP-3) and Increased Glomerular Factor H-Related Protein-5 (FHR5) Deposition. <i>Kidney International Reports</i> , 2018, 3, 426-438.	0.4	57
45	Circulating complement factor H-related protein 5 levels contribute to development and progression of IgA nephropathy. <i>Kidney International</i> , 2018, 94, 150-158.	2.6	57
46	Continual Low-Level Activation of the Classical Complement Pathway. <i>Journal of Experimental Medicine</i> , 2001, 194, 747-756.	4.2	56
47	Type I interferons affect the metabolic fitness of CD8+ T cells from patients with systemic lupus erythematosus. <i>Nature Communications</i> , 2021, 12, 1980.	5.8	56
48	The complement factor H-related proteins. <i>Immunological Reviews</i> , 2016, 274, 191-201.	2.8	54
49	SLE with C1q deficiency treated with fresh frozen plasma: a 10-year experience. <i>Rheumatology</i> , 2010, 49, 823-824.	0.9	53
50	Binding of factor H to tubular epithelial cells limits interstitial complement activation in ischemic injury. <i>Kidney International</i> , 2011, 80, 165-173.	2.6	53
51	Design and Evaluation of Meningococcal Vaccines through Structure-Based Modification of Host and Pathogen Molecules. <i>PLoS Pathogens</i> , 2012, 8, e1002981.	2.1	53
52	Are anti-C1q antibodies different from other SLE autoantibodies?. <i>Nature Reviews Rheumatology</i> , 2010, 6, 490-493.	3.5	52
53	Update on C3 glomerulopathy. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 717-725.	0.4	52
54	C3 Glomerulopathy: The Genetic and Clinical Findings in Dense Deposit Disease and C3 Glomerulonephritis. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 465-471.	1.5	50

#	ARTICLE	IF	CITATIONS
55	Competition between antagonistic complement factors for a single protein on <i>N. meningitidis</i> rules disease susceptibility. <i>ELife</i> , 2014, 3, .	2.8	50
56	Detection of glomerular complement C3 fragments by magnetic resonance imaging in murine lupus nephritis. <i>Kidney International</i> , 2012, 81, 152-159.	2.6	47
57	Factor H facilitates the clearance of GBM bound iC3b by controlling C3 activation in fluid phase. <i>Molecular Immunology</i> , 2009, 46, 1942-1950.	1.0	46
58	Atypical hemolytic uremic syndrome and genetic aberrations in the complement factor H-related 5 gene. <i>Journal of Human Genetics</i> , 2012, 57, 459-464.	1.1	43
59	Complement activation in IgA nephropathy. <i>Seminars in Immunopathology</i> , 2021, 43, 679-690.	2.8	42
60	Decay-Accelerating Factor Suppresses Complement C3 Activation and Retards Atherosclerosis in Low-Density Lipoprotein Receptor-Deficient Mice. <i>American Journal of Pathology</i> , 2009, 175, 1757-1767.	1.9	41
61	IgM exacerbates glomerular disease progression in complement-induced glomerulopathy. <i>Kidney International</i> , 2015, 88, 528-537.	2.6	41
62	An Engineered Complement Factor H Construct for Treatment of C3 Glomerulopathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 1649-1661.	3.0	41
63	Ultraviolet-Radiation-Induced Keratinocyte Apoptosis in C1q-Deficient Mice. <i>Journal of Investigative Dermatology</i> , 2001, 117, 52-58.	0.3	40
64	Eculizumab as rescue therapy in severe resistant lupus nephritis: Fig. 1. <i>Rheumatology</i> , 2015, 54, kev307.	0.9	40
65	Triglyceride-Rich Lipoproteins Modulate the Distribution and Extravasation of Ly6C/Gr1low Monocytes. <i>Cell Reports</i> , 2015, 12, 1802-1815.	2.9	33
66	Glomerular membrane attack complex is not a reliable marker of ongoing C5 activation in lupus nephritis. <i>Kidney International</i> , 2019, 95, 655-665.	2.6	33
67	O- and N-Glycosylation of Serum Immunoglobulin A is Associated with IgA Nephropathy and Glomerular Function. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2455-2465.	3.0	33
68	Partial Complement Factor H Deficiency Associates with C3 Glomerulopathy and Thrombotic Microangiopathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 1334-1342.	3.0	30
69	Complement factor H-deficient mice develop spontaneous hepatic tumors. <i>Journal of Clinical Investigation</i> , 2020, 130, 4039-4054.	3.9	30
70	Regulating complement in the kidney: insights from CFHR5 nephropathy. <i>DMM Disease Models and Mechanisms</i> , 2011, 4, 721-726.	1.2	27
71	C3 dysregulation due to factor H deficiency is mannan-binding lectin-associated serine proteases (MASP)-1 and MASP-3 independent <i>in vivo</i> . <i>Clinical and Experimental Immunology</i> , 2014, 176, 84-92.	1.1	27
72	IgA1 Glycosylation Is Heritable in Healthy Twins. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 64-68.	3.0	27

#	ARTICLE	IF	CITATIONS
73	Efficacy of Targeted Complement Inhibition in Experimental C3 Glomerulopathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 405-416.	3.0	26
74	Essential Role of Surface-Bound Complement Factor H in Controlling Immune Complex-Induced Arthritis. <i>Journal of Immunology</i> , 2013, 190, 3560-3569.	0.4	23
75	Nonfunctional Variant 3 Factor H Binding Proteins as Meningococcal Vaccine Candidates. <i>Infection and Immunity</i> , 2014, 82, 1157-1163.	1.0	23
76	Autoantibody-dependent amplification of inflammation in SLE. <i>Cell Death and Disease</i> , 2020, 11, 729.	2.7	23
77	Hyperfunctional complement C3 promotes C5-dependent atypical hemolytic uremic syndrome in mice. <i>Journal of Clinical Investigation</i> , 2019, 129, 1061-1075.	3.9	23
78	Crry deficiency in complement sufficient mice: C3 consumption occurs without associated renal injury. <i>Molecular Immunology</i> , 2009, 46, 803-811.	1.0	22
79	Complement Factor H Serum Levels Determine Resistance to Pneumococcal Invasive Disease. <i>Journal of Infectious Diseases</i> , 2016, 213, 1820-1827.	1.9	17
80	Complement factor H protects mice from ischemic acute kidney injury but is not critical for controlling complement activation by glomerular IgM. <i>European Journal of Immunology</i> , 2018, 48, 791-802.	1.6	17
81	Glomerular Complement Factor H-Related Protein 5 (FHR5) Is Highly Prevalent in C3 Glomerulopathy and Associated With Renal Impairment. <i>Kidney International Reports</i> , 2019, 4, 1387-1400.	0.4	17
82	Distinct roles for the complement regulators factor H and Crry in protection of the kidney from injury. <i>Kidney International</i> , 2016, 90, 109-122.	2.6	16
83	Annexin A2 Enhances Complement Activation by Inhibiting Factor H. <i>Journal of Immunology</i> , 2016, 196, 1355-1365.	0.4	16
84	Gain-of-function factor H-related 5 protein impairs glomerular complement regulation resulting in kidney damage. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	15
85	Improving Clinical Trials for Anticomplement Therapies in Complement-Mediated Glomerulopathies: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. <i>American Journal of Kidney Diseases</i> , 2022, 79, 570-581.	2.1	15
86	Complement factor H contributes to mortality in humans and mice with bacterial meningitis. <i>Journal of Neuroinflammation</i> , 2019, 16, 279.	3.1	13
87	Association of Histologic Parameters with Outcome in C3 Glomerulopathy and Idiopathic Immunoglobulin-Associated Membranoproliferative Glomerulonephritis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 994-1007.	2.2	13
88	Altered expression of signalling lymphocyte activation molecule receptors in T-cells from lupus nephritis patients—a potential biomarker of disease activity. <i>Rheumatology</i> , 2017, 56, 1206-1216.	0.9	12
89	Complement Factor H Modulates Splenic B Cell Development and Limits Autoantibody Production. <i>Frontiers in Immunology</i> , 2019, 10, 1607.	2.2	12
90	C3 Glomerulopathy and Related Disorders in Children. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1639-1651.	2.2	12

#	ARTICLE	IF	CITATIONS
91	Factor H-Related Protein 1 Drives Disease Susceptibility and Prognosis in C3 Glomerulopathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 1137-1153.	3.0	12
92	Experimental Models of Membranoproliferative Glomerulonephritis, Including Dense Deposit Disease. <i>Contributions To Nephrology</i> , 2011, 169, 198-210.	1.1	11
93	Clusters Not Classifications: Making Sense of Complement-Mediated Kidney Injury. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 9-12.	3.0	10
94	Complement Regulatory Protein Factor H Is a Soluble Prion Receptor That Potentiates Peripheral Prion Pathogenesis. <i>Journal of Immunology</i> , 2017, 199, 3821-3827.	0.4	9
95	Defining the Glycosaminoglycan Interactions of Complement Factor H-Related Protein 5. <i>Journal of Immunology</i> , 2021, 207, 534-541.	0.4	9
96	Circulating FH Protects Kidneys From Tubular Injury During Systemic Hemolysis. <i>Frontiers in Immunology</i> , 2020, 11, 1772.	2.2	8
97	Murine Factor H Co-Produced in Yeast With Protein Disulfide Isomerase Ameliorated C3 Dysregulation in Factor H-Deficient Mice. <i>Frontiers in Immunology</i> , 2021, 12, 681098.	2.2	8
98	Atypical hemolytic uremic syndrome: telling the difference between H and Y. <i>Kidney International</i> , 2010, 78, 721-723.	2.6	7
99	Complement receptor 3 mediates renal protection in experimental C3 glomerulopathy. <i>Kidney International</i> , 2016, 89, 823-832.	2.6	7
100	Adeno-Associated Virus Vector Gene Delivery Elevates Factor I Levels and Downregulates the Complement Alternative Pathway <i>In Vivo</i> . <i>Human Gene Therapy</i> , 2021, 32, 1370-1381.	1.4	7
101	Homodimeric Minimal Factor H: In Vivo Tracking and Extended Dosing Studies in Factor H Deficient Mice. <i>Frontiers in Immunology</i> , 2021, 12, 752916.	2.2	7
102	Relationship between complotype and reported severity of systemic allergic reactions to peanut. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 129, 1398-1401.e3.	1.5	5
103	SARS-CoV-2 Antibody Point-of-Care Testing in Dialysis and Kidney Transplant Patients With COVID-19. <i>Kidney Medicine</i> , 2021, 3, 54-59.e1.	1.0	5
104	Complement and kidney disease, new insights. <i>Current Opinion in Nephrology and Hypertension</i> , 2021, 30, 310-316.	1.0	5
105	Complement activity is regulated in C3 glomerulopathy by IgG-factor H fusion proteins with and without properdin targeting domains. <i>Kidney International</i> , 2021, 99, 396-404.	2.6	4
106	Lateral medullary syndrome with anti-neuronal antibodies (anti-Ta/Ma2) in primary Sjogren's syndrome. <i>Rheumatology</i> , 2009, 48, 1174-1176.	0.9	3
107	Complement alternative pathway genetic variation and Dengue infection in the Thai population. <i>Clinical and Experimental Immunology</i> , 2013, 174, 326-334.	1.1	3
108	Immune gene expression and functional networks in distinct lupus nephritis classes. <i>Lupus Science and Medicine</i> , 2022, 9, e000615.	1.1	3

#	ARTICLE	IF	CITATIONS
109	False-positive results obtained using the Mantoux test in Behçet's syndrome: Comment on the article by Garcia-Porrà et al. Arthritis and Rheumatism, 2000, 43, 2855-2855.	6.7	2
110	Painful myositis in the anti-synthetase syndrome with anti-PL12 antibodies. Rheumatology International, 2012, 32, 825-827.	1.5	2
111	Membranoproliferative and C3-Mediated GN in Children. , 2016, , 1035-1053.		2
112	Successful simultaneous liver&kidney transplantation for renal failure associated with hereditary complement C3 deficiency. American Journal of Transplantation, 2020, 20, 2260-2263.	2.6	2
113	MO126CLINICAL AND BIOMARKER CHARACTERISTICS OF PATIENTS WITH C3G OR IC-MPGN ENROLLED IN TWO PHASE II STUDIES INVESTIGATING THE FACTOR D INHIBITOR DANICOPAN*. Nephrology Dialysis Transplantation, 2021, 36, .	0.4	2
114	Complement activation during cardiopulmonary bypass and association with clinical outcomes. EJHaem, 2022, 3, 86-96.	0.4	2
115	Membranoproliferative Glomerulonephritis and C3 Glomerulopathy in Children. , 2021, , 1-31.		1
116	Conversion of the Liver into a Biofactory for DNaseI Using Adeno-Associated Virus Vector Gene Transfer Reduces Neutrophil Extracellular Traps in a Model of Systemic Lupus Erythematosus. Human Gene Therapy, 2022, 33, 560-571.	1.4	1
117	Genetic Manipulation. , 2006, , 563-589.		0
118	Disorders of complement regulation. Drug Discovery Today: Disease Models, 2014, 11, 29-35.	1.2	0
119	Membranoproliferative and C3-Mediated GN in Children. , 2015, , 1-22.		0
120	ATYPICAL HEMOLYTIC UREMIC SYNDROME AND C3 GLOMERULOPATHY: CONCLUSIONS FROM A «KIDNEY DISEASE: IMPROVING GLOBAL OUTCOMES» (KDIGO) CONTROVERSIES CONFERENCE. Nephrology (Saint-Petersburg), 2018, 22, 18-39.	0.1	0